Skip to main content

Provider Alert: Zinbryta

On March 2, 2018, Biogen and AbbVie announced the voluntary worldwide withdrawal of Zinbryta® (daclizumab), a medicine used to treat relapsing multiple sclerosis. This action was taken following reports of serious inflammatory brain disorders associated with its use, including encephalitis and meningoencephalitis. The supply of Zinbryta will be phased out by April 30, 2018.

To allow patients time to transition from Zinbryta to an appropriate alternative medicine, Biogen and AbbVie are advising all health care professionals to contact their patients.

All patients transitioning from Zinbryta should undergo safety assessments in accordance with the Risk Evaluation and Mitigation Strategy (REMS) program and the approved US Prescribing Information. To report suspected adverse reactions, contact Biogen at 1-800-456-2255 or the Food and Drug Administration at 1-800-FDA-1088 or online.

Any questions or concerns about the withdrawal can be directed to the manufacturers’ service center at 1-800-456-2255 or the manufacturer’s website.

Published on: March 22, 2018, 12:00 p.m. ET
Last updated on: April 26, 2021, 02:09 a.m. ET